BBC vs. ARKG
BBC (Virtus LifeSci Biotech Clinical Trials ETF) and ARKG (ARK Genomic Revolution Multi-Sector ETF) are both Health & Biotech Equities funds. BBC is passively managed, while ARKG is actively managed. Over the past 10 years, BBC returned 9.79%/yr vs 8.25%/yr for ARKG. Their 0.79 correlation means they have sometimes moved together and sometimes differently. BBC charges 0.79%/yr vs 0.75%/yr for ARKG.
Performance
BBC vs. ARKG - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBC achieves a 26.39% return, which is significantly lower than ARKG's 33.10% return. Over the past 10 years, BBC has outperformed ARKG with an annualized return of 9.79%, while ARKG has yielded a comparatively lower 8.25% annualized return.
BBC
- 1D
- -3.05%
- 1M
- -7.68%
- 6M
- 19.33%
- YTD
- 26.39%
- 1Y
- 131.04%
- 3Y*
- 28.17%
- 5Y*
- 2.62%
- 10Y*
- 9.79%
- ALL TIME*
- 6.26%
ARKG
- 1D
- -1.78%
- 1M
- -10.14%
- 6M
- 26.72%
- YTD
- 33.10%
- 1Y
- 63.67%
- 3Y*
- 1.35%
- 5Y*
- -14.38%
- 10Y*
- 8.25%
- ALL TIME*
- 6.19%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $92.48M | $118.08M | $121.77M | |
| $567.19K | $1.45M | $1.29M |
BBC vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BBC Virtus LifeSci Biotech Clinical Trials ETF | 26.39% | 63.77% | -1.11% | -1.80% | -35.13% | -22.31% | 30.32% | 63.81% | -18.29% | 57.85% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 33.10% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 44.00% | -1.26% | 46.61% |
Correlation
The correlation between BBC and ARKG is 0.65, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.65 |
Correlation (3Y) Balances recent behavior with more history. | 0.75 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.80 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.80 |
Correlation (All Time) Calculated using the full available price history since Dec 17, 2014 | 0.79 |
The correlation between BBC and ARKG shifts across timeframes, from 0.65 (1 year) to 0.80 (5 years), reflecting how their relationship changes across market environments.
BBC vs. ARKG - Sectors Allocation Comparison
Sectors
BBC
ARKG
Healthcare
Financial Services
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
Utilities
-
-
Healthcare
BBC
ARKG
Financial Services
BBC
ARKG
Basic Materials
BBC
-
ARKG
-
Communication Services
BBC
-
ARKG
-
Consumer Cyclical
BBC
-
ARKG
-
Consumer Defensive
BBC
-
ARKG
-
Energy
BBC
-
ARKG
-
Industrials
BBC
-
ARKG
-
Real Estate
BBC
-
ARKG
-
Technology
BBC
-
ARKG
Utilities
BBC
-
ARKG
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBC vs. ARKG — Risk / Return Rank
BBC
ARKG
BBC vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBC | ARKG | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.11 | ||
| Sortino ratioReturn per unit of downside risk | +1.86 | ||
| Omega ratioGain probability vs. loss probability | 1.47 | 1.25 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 8.58 | 2.26 | +6.32 |
| Martin ratioReturn relative to average drawdown | 23.49 | 5.42 | +18.07 |
Loading charts...
Drawdowns
BBC vs. ARKG - Drawdown Comparison
The maximum BBC drawdown since its inception was -76.85%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for BBC and ARKG.
Loading charts...
Drawdown Indicators
| BBC | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -76.85% | -83.59% | +6.74% |
Max Drawdown (1Y)Largest decline over 1 year | -15.10% | -27.51% | +12.41% |
Max Drawdown (3Y)Largest decline over 3 years | -54.45% | -46.45% | -8.00% |
Max Drawdown (5Y)Largest decline over 5 years | -70.92% | -79.26% | +8.34% |
Max Drawdown (10Y)Largest decline over 10 years | -76.85% | -83.59% | +6.74% |
Current DrawdownCurrent decline from peak | -18.87% | -65.50% | +46.63% |
Average DrawdownAverage peak-to-trough decline | -36.88% | -36.27% | -0.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.51% | 11.46% | -5.95% |
Volatility
BBC vs. ARKG - Volatility Comparison
Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ARK Genomic Revolution Multi-Sector ETF (ARKG) have volatilities of 10.52% and 10.47%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBC | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.52% | 10.47% | +0.05% |
Volatility (6M)Calculated over the trailing 6-month period | 26.31% | 31.28% | -4.97% |
Volatility (1Y)Calculated over the trailing 1-year period | 36.55% | 43.11% | -6.56% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 39.60% | 46.17% | -6.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 37.72% | 41.44% | -3.72% |
BBC vs. ARKG - Expense Ratio Comparison
BBC has a 0.79% expense ratio, which is higher than ARKG's 0.75% expense ratio.
Dividends
BBC vs. ARKG - Dividend Comparison
BBC's dividend yield for the trailing twelve months is around 1.34%, while ARKG has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% | 0.00% | 0.00% |
BBC Virtus LifeSci Biotech Clinical Trials ETF | 1.34% | 1.70% | 1.00% | 0.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.09% | 0.00% | 0.51% |
Frequently Asked Questions
BBC and ARKG have a correlation of 0.65, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BBC has higher volatility (10.52%) compared to ARKG (10.47%). In terms of maximum drawdown, BBC dropped -76.85% vs ARKG's -83.59%.
On 10-year performance, BBC leads with 9.79% vs 8.25% for ARKG. On fees, ARKG is cheaper at 0.75% per year. Their volatility is very similar. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, BBC has performed better with a 9.79% return vs 8.25%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
ARKG is cheaper with a 0.75% expense ratio, compared with 0.79% for BBC.
BBC has the higher dividend yield at 1.34%, compared with 0.00% for ARKG.
They also come from different issuers: Virtus and ARK. Their fees differ too: 0.79% for BBC and 0.75% for ARKG.
BBC currently has the higher Sharpe Ratio (3.55 vs 1.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBC and ARKG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer